The first second-generation adenosine drug enters the US market

Purinergic Signalling

Volumn 4, Issue 4, 2008, Pages 407-408

  Pelleg, Amir ^a   Belardinelli, Luiz ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b CV THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56549120785     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-008-9114-2     Document Type: Article

References (5)

1. Dhalla AK, Xu J, Kussmaul W, Kurnik PP, Pelleg A, Belardinelli L (2004) Differential vasodilatory effects of CVT-3146, an A 2A adenosine receptor agonist, in various vascular beds in anesthetized dogs. J Am Coll Cardiol 43:367A
2. Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, Ongini E, Baker SP, Belardinelli L (1998) A2A-adenosine receptor reserve for coronary vasodilation. Circulation 98:711-718
3. Verani MS (1991) Pharmacological stress with adenosine for myocardial perfusion imaging. Semin Nucl Med 21:266-272
4. Trochu JN, Zhao G, Post H, Xu X, Belardinelli L, Belloni FL, Hintze TH (2003) Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 41:132-139
5. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA (2007) Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 14:514-520